/Vertex%20Pharmaceuticals%2C%20Inc_%20HQ%20in%20Boston-by%20Tada%20Images%20via%20Shuttershock.jpg)
With a market cap of $116.9 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a global biotechnology company focused on developing and commercializing transformative medicines for serious diseases, including cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia, and acute pain. It serves patients worldwide through specialty pharmacies, distributors, hospitals, and clinics.
Companies valued at $10 billion or more are generally considered “large-cap” stocks, and Vertex Pharmaceuticals fits this criterion perfectly. The company markets several approved therapies, such as TRIKAFTA/KAFTRIO, ALYFTREK, CASGEVY, and JOURNAVX, while advancing a diverse pipeline of innovative treatments across multiple therapeutic areas.
